Dyne Therapeutics, Inc. (DYN)
USD 11.86
(-1.08%)
USD 11.86
(-1.08%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 242.16 Million USD | 42.47% |
| 2022 | 170.96 Million USD | 13.96% |
| 2021 | 150.02 Million USD | 155.81% |
| 2020 | 58.64 Million USD | 324.18% |
| 2019 | 13.82 Million USD | 188.34% |
| 2018 | 4.79 Million USD | -97.46% |
| 2017 | 189 Million USD | 17.39% |
| 2016 | 161 Million USD | 25.78% |
| 2015 | 128 Million USD | 141.56% |
| 2014 | -308 Million USD | -417.53% |
| 2013 | 97 Million USD | 219.75% |
| 2012 | -81 Million USD | -160.0% |
| 2011 | 135 Million USD | -17.18% |
| 2010 | 163 Million USD | 131.41% |
| 2009 | -519 Million USD | -5.06% |
| 2008 | -494 Million USD | -143.35% |
| 2007 | -203 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 69.15 Million USD | 3.03% |
| 2024 Q2 | 71.56 Million USD | 4.06% |
| 2023 Q3 | 62.27 Million USD | -6.69% |
| 2023 Q2 | 66.73 Million USD | 46.79% |
| 2023 FY | 239.7 Million USD | 40.21% |
| 2023 Q1 | 45.46 Million USD | 13.25% |
| 2023 Q4 | 67.12 Million USD | 7.79% |
| 2022 Q3 | 42.27 Million USD | -19.86% |
| 2022 FY | 170.96 Million USD | 13.96% |
| 2022 Q4 | 40.14 Million USD | -5.05% |
| 2022 Q1 | 35.78 Million USD | -31.13% |
| 2022 Q2 | 52.75 Million USD | 47.43% |
| 2021 Q3 | 42.76 Million USD | 41.77% |
| 2021 FY | 150.02 Million USD | 155.81% |
| 2021 Q4 | 51.96 Million USD | 21.5% |
| 2021 Q2 | 30.16 Million USD | 20.02% |
| 2021 Q1 | 25.13 Million USD | -12.12% |
| 2020 Q2 | 8.67 Million USD | 10.47% |
| 2020 Q1 | 7.85 Million USD | 43.56% |
| 2020 Q3 | 13.52 Million USD | 55.85% |
| 2020 FY | 58.64 Million USD | 324.18% |
| 2020 Q4 | 28.6 Million USD | 111.54% |
| 2019 Q3 | 3.62 Million USD | 96.32% |
| 2019 Q1 | 1.84 Million USD | 0.0% |
| 2019 FY | 13.82 Million USD | 188.34% |
| 2019 Q4 | 5.47 Million USD | 50.73% |
| 2019 Q2 | 1.84 Million USD | 0.0% |
| 2018 FY | 4.79 Million USD | -97.46% |
| 2017 FY | 189 Million USD | 17.39% |
| 2017 Q4 | 63 Million USD | 43.18% |
| 2017 Q3 | 44 Million USD | 4.76% |
| 2017 Q2 | 42 Million USD | 5.0% |
| 2017 Q1 | 40 Million USD | -9.09% |
| 2016 Q1 | 37 Million USD | 8.82% |
| 2016 Q2 | 39 Million USD | 5.41% |
| 2016 Q3 | 41 Million USD | 5.13% |
| 2016 Q4 | 44 Million USD | 7.32% |
| 2016 FY | 161 Million USD | 25.78% |
| 2015 FY | 128 Million USD | 141.56% |
| 2015 Q4 | 34 Million USD | 17.24% |
| 2015 Q3 | 29 Million USD | -17.14% |
| 2015 Q2 | 35 Million USD | 16.67% |
| 2015 Q1 | 30 Million USD | 109.74% |
| 2014 Q1 | 26 Million USD | -7.14% |
| 2014 Q4 | -308 Million USD | -1332.0% |
| 2014 Q3 | 25 Million USD | -13.79% |
| 2014 Q2 | 29 Million USD | 11.54% |
| 2014 FY | -308 Million USD | -417.53% |
| 2013 Q3 | 22 Million USD | -12.0% |
| 2013 Q4 | 28 Million USD | 27.27% |
| 2013 FY | 97 Million USD | 219.75% |
| 2013 Q1 | 22 Million USD | 127.16% |
| 2013 Q2 | 25 Million USD | 13.64% |
| 2012 Q4 | -81 Million USD | 36.22% |
| 2012 Q3 | -127 Million USD | -388.64% |
| 2012 FY | -81 Million USD | -160.0% |
| 2012 Q2 | 44 Million USD | 91.3% |
| 2012 Q1 | 23 Million USD | -39.47% |
| 2011 Q3 | 32 Million USD | 28.0% |
| 2011 Q1 | 40 Million USD | -24.53% |
| 2011 Q2 | 25 Million USD | -37.5% |
| 2011 Q4 | 38 Million USD | 18.75% |
| 2011 FY | 135 Million USD | -17.18% |
| 2010 Q1 | -113 Million USD | 22.6% |
| 2010 Q4 | 53 Million USD | 3.92% |
| 2010 FY | 163 Million USD | 131.41% |
| 2010 Q3 | 51 Million USD | 3.12% |
| 2010 Q2 | 49.45 Million USD | 143.77% |
| 2009 Q1 | -51 Million USD | 59.84% |
| 2009 Q4 | -146 Million USD | -36.45% |
| 2009 FY | -519 Million USD | -5.06% |
| 2009 Q3 | -107 Million USD | 50.23% |
| 2009 Q2 | -215 Million USD | -321.57% |
| 2008 Q4 | -127 Million USD | 2.31% |
| 2008 FY | -494 Million USD | -143.35% |
| 2008 Q1 | -112 Million USD | -180.0% |
| 2008 Q2 | -125 Million USD | -11.61% |
| 2008 Q3 | -130 Million USD | -4.0% |
| 2007 Q3 | -62 Million USD | -29.17% |
| 2007 FY | -203 Million USD | 0.0% |
| 2007 Q4 | -40 Million USD | 35.48% |
| 2007 Q2 | -48 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Absci Corporation | 73.66 Million USD | -228.73% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 24.738% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 86.547% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -2336.815% |
| Apollomics, Inc. | 54.14 Million USD | -347.289% |
| 180 Life Sciences Corp. | 13.47 Million USD | -1696.787% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -671.782% |
| Bicycle Therapeutics plc | 216.92 Million USD | -11.636% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -185.852% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -40.872% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -415.173% |
| Chimerix, Inc. | 93.38 Million USD | -159.305% |
| CRISPR Therapeutics AG | 463.49 Million USD | 47.753% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -617.985% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -107.948% |
| Fortress Biotech, Inc. | 200.19 Million USD | -20.963% |
| Fortress Biotech, Inc. | 200.19 Million USD | -20.963% |
| Gritstone bio, Inc. | 148.37 Million USD | -63.211% |
| Allakos Inc. | 196.05 Million USD | -23.517% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -341.934% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -69.982% |
| Cytokinetics, Incorporated | 173.61 Million USD | -39.485% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -835.53% |
| Innoviva, Inc. | 132.15 Million USD | -83.242% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -3048.133% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1950.993% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -90.586% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -1877998.34% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -136.122% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -172.502% |
| ImmuCell Corporation | 9.61 Million USD | -2417.967% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -53.448% |
| Incyte Corporation | 1.19 Billion USD | 79.659% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -82.688% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3498.926% |
| Mustang Bio, Inc. | 48.5 Million USD | -399.293% |
| MiMedx Group, Inc. | 229.72 Million USD | -5.413% |
| MEI Pharma, Inc. | 34.78 Million USD | -596.168% |
| MacroGenics, Inc. | 217.21 Million USD | -11.485% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -2642.108% |
| Mereo BioPharma Group plc | 35.84 Million USD | -575.638% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -1253.427% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -50.842% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -40.915% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -948.838% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -1424.374% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -2254.516% |
| NextCure, Inc. | 67.63 Million USD | -258.032% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -347.785% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -717.949% |
| Onconetix, Inc. | 34.9 Million USD | -593.726% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -1799.906% |
| Opthea Limited | 191.96 Million USD | -26.147% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -305.814% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -8700.818% |
| PDS Biotechnology Corporation | 43.04 Million USD | -462.576% |
| Precigen, Inc. | 84.18 Million USD | -187.668% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -233.713% |
| Prime Medicine, Inc. | 186.63 Million USD | -29.749% |
| PureTech Health plc | 144.59 Million USD | -67.474% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 6.738% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 91.398% |
| Replimune Group, Inc. | 234.77 Million USD | -3.147% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2697.406% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -85.902% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -1147.067% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 51.448% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -896.281% |
| Sesen Bio, Inc. | 78.38 Million USD | -208.955% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -5.896% |
| Solid Biosciences Inc. | 104.31 Million USD | -132.145% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -5.309% |
| SciSparc Ltd. | 9.01 Million USD | -2587.404% |
| Sutro Biopharma, Inc. | 243 Million USD | 0.349% |
| TG Therapeutics, Inc. | 198.47 Million USD | -22.011% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -99.463% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -3145.704% |
| Travere Therapeutics, Inc. | 472 Million USD | 48.695% |
| UroGen Pharma Ltd. | 138.88 Million USD | -74.358% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -243.035% |
| XOMA Corporation | 46.46 Million USD | -421.193% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 4.114% |
| AbCellera Biologics Inc. | 275.23 Million USD | 12.015% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -326.65% |
| Cassava Sciences, Inc. | 105.95 Million USD | -128.547% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1640.965% |
| Precision BioSciences, Inc. | 92.46 Million USD | -161.902% |
| Dyadic International, Inc. | 9.15 Million USD | -2545.8% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -2810.951% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -988.222% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -715.855% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -84.585% |
| IGM Biosciences, Inc. | 265.59 Million USD | 8.821% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -125.221% |
| Acelyrin, Inc. | 422.06 Million USD | 42.624% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -1249.919% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -187.184% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -3497.208% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 1.16% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -686.981% |
| Senti Biosciences, Inc. | 94.7 Million USD | -155.701% |
| Mesoblast Limited | 5.9 Million USD | -4003.05% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 0.803% |
| ChromaDex Corporation | 56.37 Million USD | -329.525% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -626.557% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -20.41% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -2911.251% |
| Seer, Inc. | 110.49 Million USD | -119.171% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -43.771% |
| Novavax, Inc. | 779.12 Million USD | 68.919% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -1443.437% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 4.677% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -363.459% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 2.013% |
| Celcuity Inc. | 66.23 Million USD | -265.636% |
| ContextLogic Inc. | 387 Million USD | 37.426% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -44.293% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -639.516% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 92.562% |
| Amarin Corporation plc | 272.35 Million USD | 11.087% |
| AnaptysBio, Inc. | 181.56 Million USD | -33.373% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -738.569% |
| Aptorum Group Limited | 10.56 Thousand USD | -2291798.542% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -118.426% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 45.672% |
| Ardelyx, Inc. | 169.93 Million USD | -42.501% |
| Celularity Inc. | 215.05 Million USD | -12.603% |
| Omeros Corporation | 94.75 Million USD | -155.577% |
| Humacyte, Inc. | 23.49 Million USD | -930.608% |
| Immunocore Holdings plc | 308.04 Million USD | 21.386% |
| IO Biotech, Inc. | 91.44 Million USD | -164.823% |
| GT Biopharma, Inc. | 13.57 Million USD | -1683.751% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -224.353% |
| Summit Therapeutics Inc. | 87.68 Million USD | -176.17% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -721.752% |
| Pulmatrix, Inc. | 22.03 Million USD | -998.838% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 56.096% |
| Evogene Ltd. | 27.79 Million USD | -771.4% |
| CorMedix Inc. | 48.95 Million USD | -394.634% |
| BioLineRx Ltd. | 50.8 Million USD | -376.678% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -610.465% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -639.652% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 81.54% |
| scPharmaceuticals Inc. | 65.17 Million USD | -271.539% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -113.417% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 34.304% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1950.993% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -896.281% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -40.083% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -547.354% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -841.971% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -95.998% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -191.575% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -355.822% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -2764.895% |
| Daré Bioscience, Inc. | 33.6 Million USD | -620.519% |
| bluebird bio, Inc. | 240.23 Million USD | -0.803% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 86.133% |
| DBV Technologies S.A. | 92.16 Million USD | -162.763% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 1.222% |
| Galecto, Inc. | 35.62 Million USD | -579.715% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -553.362% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -290.068% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -10.159% |
| GlycoMimetics, Inc. | 39.28 Million USD | -516.419% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 18.111% |
| ADMA Biologics, Inc. | 66.58 Million USD | -263.683% |
| Clene Inc. | 41.07 Million USD | -489.589% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 31.213% |
| Aptose Biosciences Inc. | 52.35 Million USD | -362.53% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -1580.47% |
| Soligenix, Inc. | 7.79 Million USD | -3006.532% |
| Century Therapeutics, Inc. | 56.07 Million USD | -331.885% |
| Kura Oncology, Inc. | 165.8 Million USD | -46.053% |
| Surrozen, Inc. | 18.55 Million USD | -1205.456% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -111.482% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -9658.148% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -124.853% |
| Autolus Therapeutics plc | 196.72 Million USD | -23.096% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -186.051% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -1149.353% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -60.867% |
| GRI Bio, Inc. | 11.33 Million USD | -2037.352% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -3332.147% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -198.737% |
| INmune Bio, Inc. | 29.89 Million USD | -710.015% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -40.34% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -500.685% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1415.467% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -2841.022% |
| Jaguar Health, Inc. | 42.01 Million USD | -476.37% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -1438.362% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -289.967% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -640.217% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 12.162% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 19.668% |
| Verastem, Inc. | 92.08 Million USD | -162.979% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -30.387% |
| Histogen Inc. | 14.27 Million USD | -1596.763% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -1408.972% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 67.887% |
| Surrozen, Inc. | 18.55 Million USD | -1205.456% |
| Organovo Holdings, Inc. | 14.91 Million USD | -1523.614% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -4657.383% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -3072.632% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -35.942% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -399.839% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -1475.901% |
| Kronos Bio, Inc. | 128.11 Million USD | -89.015% |
| Turnstone Biologics Corp. | 78.33 Million USD | -209.125% |
| Synaptogenix, Inc. | 8.31 Million USD | -2812.753% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -1560.236% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -83.213% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 4.305% |
| Exelixis, Inc. | 1.58 Billion USD | 84.739% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -4.358% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 71.684% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -251.668% |
| ESSA Pharma Inc. | 32.13 Million USD | -653.598% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -1380.188% |
| Avid Bioservices, Inc. | 25.99 Million USD | -831.536% |
| Insmed Incorporated | 949.26 Million USD | 74.489% |
| MediWound Ltd. | 18.86 Million USD | -1183.453% |
| OmniAb, Inc. | 83.89 Million USD | -188.649% |
| Alector, Inc. | 248.8 Million USD | 2.669% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -3.352% |
| Zai Lab Limited | 547.47 Million USD | 55.768% |
| AlloVir, Inc. | 180.93 Million USD | -33.841% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 39.255% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -118.597% |
| Aura Biosciences, Inc. | 84.99 Million USD | -184.927% |
| Immunic, Inc. | 99.22 Million USD | -144.058% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -52.292% |
| Veracyte, Inc. | 357.93 Million USD | 32.344% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 97.314% |
| FibroGen, Inc. | 398.11 Million USD | 39.173% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1604.166% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 6.654% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -3415.736% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -3298.416% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -835.964% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 23.498% |
| Fortrea Holdings Inc. | 457.3 Million USD | 47.045% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -346.151% |
| XBiotech Inc. | 37.51 Million USD | -545.593% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -251.668% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -43.057% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -539.473% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -1072.754% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -70.463% |
| Agenus Inc. | 78.18 Million USD | -209.737% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -144.423% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -118.724% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 74.729% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -739.529% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 43.767% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -985.524% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -51.553% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -4278.309% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -851.184% |
| Lantern Pharma Inc. | 17.87 Million USD | -1254.558% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -463.167% |
| Ainos, Inc. | 12.95 Million USD | -1769.592% |
| Pluri Inc. | 22.48 Million USD | -977.233% |
| Prothena Corporation plc | 282.4 Million USD | 14.25% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -21.068% |
| Rallybio Corporation | 78.93 Million USD | -206.798% |
| Kodiak Sciences Inc. | 277.32 Million USD | 12.678% |
| Cue Biopharma, Inc. | 19.54 Million USD | -1139.187% |
| MeiraGTx Holdings plc | 151.07 Million USD | -60.289% |
| Annexon, Inc. | 143.72 Million USD | -68.492% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -957.061% |
| Moderna, Inc. | 6.39 Billion USD | 96.213% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -7043.422% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -178.78% |
| Blueprint Medicines Corporation | 722.86 Million USD | 66.5% |
| Immix Biopharma, Inc. | 16.14 Million USD | -1400.281% |
| CalciMedica, Inc. | 21.81 Million USD | -1009.969% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -68.977% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -41.371% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -33.569% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 17.894% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -600.396% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -233.782% |
| Nutriband Inc. | 5.73 Million USD | -4123.242% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -455.252% |
| Vor Biopharma Inc. | 126.03 Million USD | -92.137% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 79.636% |
| Alkermes plc | 996.24 Million USD | 75.693% |
| ProKidney Corp. | 151.52 Million USD | -59.82% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -226.474% |
| Arcellx, Inc. | 200.19 Million USD | -20.961% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 60.575% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -60.691% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -536.063% |
| Atai Life Sciences N.V. | 125.78 Million USD | -92.521% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -196.624% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -197.463% |
| MediciNova, Inc. | 10.9 Million USD | -2121.616% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -87.985% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -3235.783% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3921.173% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 49.164% |
| Biomea Fusion, Inc. | 126.13 Million USD | -91.986% |
| RenovoRx, Inc. | 11.39 Million USD | -2024.974% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -26.727% |
| Geron Corporation | 70.44 Million USD | -243.78% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -777.971% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -81.273% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 7.589% |
| Royalty Pharma plc | 862.4 Million USD | 71.92% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -16.427% |
| Imunon, Inc. | 20.31 Million USD | -1092.304% |
| BioAtla, Inc. | 129.68 Million USD | -86.728% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -185.172% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -479.918% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -16.529% |
| Structure Therapeutics Inc. | 102.77 Million USD | -135.623% |
| 89bio, Inc. | 151.2 Million USD | -60.156% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -117.828% |
| aTyr Pharma, Inc. | 12.97 Million USD | -1765.799% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -133.621% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 4.947% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -2844.285% |
| Akari Therapeutics, Plc | 16.8 Million USD | -1340.926% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -10549.305% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 19.095% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -40.084% |
| Liquidia Corporation | 87.98 Million USD | -175.234% |
| Entera Bio Ltd. | 8.86 Million USD | -2633.205% |
| GH Research PLC | 41.22 Million USD | -487.458% |
| Vericel Corporation | 142.04 Million USD | -70.489% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -974.175% |
| Xencor, Inc. | 306.97 Million USD | 21.114% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -4808.418% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1415.467% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -1081.861% |
| Vaxcyte, Inc. | 468.04 Million USD | 48.261% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -420.309% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -26.26% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3498.926% |
| Portage Biotech Inc. | 18.19 Million USD | -1230.634% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -3235.783% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -130.716% |
| OncoCyte Corporation | 25.63 Million USD | -844.58% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -3872.73% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -2013.649% |
| Purple Biotech Ltd. | -22.46 Million USD | 1177.856% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -730.545% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -684.737% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 4.088% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -1369.43% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -717.259% |
| United Therapeutics Corporation | 885.1 Million USD | 72.64% |
| HilleVax, Inc. | 133.34 Million USD | -81.606% |
| Silo Pharma, Inc. | 3.92 Million USD | -6074.679% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -6043.051% |
| Pharming Group N.V. | 225.49 Million USD | -7.393% |
| Tharimmune, Inc. | 9.45 Million USD | -2461.146% |
| Genprex, Inc. | 31.06 Million USD | -679.645% |
| Apogee Therapeutics, Inc. | 93 Million USD | -160.381% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -29.135% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -194.615% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -31555.163% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -4345.853% |
| OKYO Pharma Limited | 8243.57 USD | -2937486.507% |
| Savara Inc. | 15.74 Million USD | -1438.025% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1287.191% |
| Curis, Inc. | 58.35 Million USD | -314.981% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -4655.279% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -796.166% |
| BeiGene, Ltd. | 3.28 Billion USD | 92.632% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -57.604% |
| Erasca, Inc. | 141.52 Million USD | -71.109% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -5249.313% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -5249.313% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -468.335% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -1585.661% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -263.056% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -457.797% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -16.351% |
| Adicet Bio, Inc. | 152.03 Million USD | -59.277% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 43.374% |
| Aditxt, Inc. | 25.95 Million USD | -833.159% |
| Adagene Inc. | 41.83 Million USD | -478.901% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -3212.705% |
| Quantum-Si incorporated | 111.65 Million USD | -116.876% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -1561.173% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -576.015% |
| Compugen Ltd. | 43.97 Million USD | -450.731% |
| Generation Bio Co. | 144.46 Million USD | -67.624% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -191.656% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -180.086% |
| Invivyd, Inc. | 205.75 Million USD | -17.694% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -235.595% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -2482.096% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -221.793% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -2254.059% |
| 2seventy bio, Inc. | 289.88 Million USD | 16.463% |
| Instil Bio, Inc. | 85.78 Million USD | -182.289% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -1790.726% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -21243.757% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3921.173% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -559.267% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -133.517% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -42.216% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 68.457% |
| Evaxion Biotech A/S | 22.27 Million USD | -987.391% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -78.659% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -3.099% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -202.911% |
| Cingulate Inc. | 22.75 Million USD | -964.019% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 3332.274% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -442.15% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -290.118% |
| Clearmind Medicine Inc. | 8.74 Million USD | -2670.304% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -188.041% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -8156.503% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -140.176% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 36.356% |
| ImmunityBio, Inc. | 362.87 Million USD | 33.265% |
| Korro Bio, Inc. | 84.53 Million USD | -186.467% |
| Kineta, Inc. | 21.15 Million USD | -1044.649% |
| BioVie Inc. | 31.95 Million USD | -657.936% |
| Codexis, Inc. | 66.51 Million USD | -264.055% |
| Celularity Inc. | 215.05 Million USD | -12.603% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -1387.847% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -6.858% |
| Virax Biolabs Group Limited | 6.54 Million USD | -3598.788% |
| Cibus, Inc. | 320.3 Million USD | 24.396% |
| IN8bio, Inc. | 30.33 Million USD | -698.24% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -89.796% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -37737.813% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 68.937% |
| Eyenovia, Inc. | 25.4 Million USD | -853.152% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -72.585% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -4253.866% |
| Elevation Oncology, Inc. | 45.44 Million USD | -432.868% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -206.019% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -427.586% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -11.899% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -2332.078% |
| Moolec Science SA | 52.75 Million USD | -359.07% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -296.091% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -420.331% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -157.422% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -399.581% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -2496.114% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -970.162% |
| Humacyte, Inc. | 23.49 Million USD | -930.608% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -202.204% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -1565.488% |
| Genelux Corporation | 24.33 Million USD | -895.118% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -613.858% |
| Notable Labs, Ltd. | 14.77 Million USD | -1539.553% |
| Immunovant, Inc. | 282.7 Million USD | 14.342% |
| Quantum-Si incorporated | 111.65 Million USD | -116.876% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -1038.675% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -137.386% |
| Acasti Pharma Inc. | 11.3 Million USD | -2042.837% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -956.502% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -485.159% |
| PepGen Inc. | 84.76 Million USD | -185.683% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -957.615% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -639.979% |
| Immuneering Corporation | 58.41 Million USD | -314.569% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -4657.383% |
| Belite Bio, Inc | 31.66 Million USD | -664.69% |
| XOMA Corporation | 46.46 Million USD | -421.193% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -258.493% |
| Bionomics Limited | 17.89 Billion USD | 98.647% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 778.705% |
| uniQure N.V. | 285.08 Million USD | 15.057% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -3212.705% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -24.693% |
| Forte Biosciences, Inc. | 32.47 Million USD | -645.642% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -2814.54% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -723.82% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -4253.866% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1604.166% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -2624.288% |
| Altimmune, Inc. | 30.55 Million USD | -692.519% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -242.506% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 778.705% |
| Peak Bio, Inc. | 1249.13 USD | -19386352.971% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -226.716% |
| Benitec Biopharma Inc. | 22.38 Million USD | -981.95% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 0.422% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -748.411% |
| Zura Bio Limited | 62.63 Million USD | -286.606% |
| PolyPid Ltd. | 21.04 Million USD | -1050.687% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -748.411% |
| argenx SE | 1.53 Billion USD | 84.209% |
| Immunome, Inc. | 122.82 Million USD | -97.168% |
| Verona Pharma plc | 67.15 Million USD | -260.622% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -835.53% |
| Shattuck Labs, Inc. | 93.61 Million USD | -158.681% |
| CervoMed Inc. | 14.95 Million USD | -1518.972% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -2734.293% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -374.827% |
| Moolec Science SA | 52.75 Million USD | -359.07% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -1372.249% |
| Design Therapeutics, Inc. | 78.19 Million USD | -209.71% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -178.216% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -1824.211% |
| Achilles Therapeutics plc | 75.25 Million USD | -221.789% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -8156.503% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -335.128% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -375.957% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -266.363% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -347.428% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -433.291% |
| Beam Therapeutics Inc. | 554.19 Million USD | 56.304% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 2.546% |
| AEON Biopharma, Inc. | 48.42 Million USD | -400.035% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -159.058% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -189.914% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -1823.922% |
| NeurAxis, Inc. | 8.82 Million USD | -2645.228% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 46.305% |
| Lumos Pharma, Inc. | 38.66 Million USD | -526.308% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -813.735% |
| Palisade Bio, Inc. | 13.32 Million USD | -1718.033% |
| Nutriband Inc. | 5.73 Million USD | -4123.242% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -175.529% |
| Neurogene Inc. | 55.58 Million USD | -335.676% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -2765.483% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -150.4% |
| Athira Pharma, Inc. | 125.46 Million USD | -93.01% |
| HCW Biologics Inc. | 21.02 Million USD | -1051.643% |
| XOMA Corporation | 46.46 Million USD | -421.193% |
| Nektar Therapeutics | 190.9 Million USD | -26.851% |
| Arvinas, Inc. | 480 Million USD | 49.55% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -10549.305% |
| Merus N.V. | 200.49 Million USD | -20.783% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -134.301% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -599.486% |
| Rezolute, Inc. | 70.38 Million USD | -244.044% |
| Clene Inc. | 41.07 Million USD | -489.589% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -1378.538% |
| BeyondSpring Inc. | 24.86 Million USD | -873.907% |
| Synlogic, Inc. | 58.53 Million USD | -313.726% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -1253.465% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -5290.962% |
| Peak Bio, Inc. | 1249.13 USD | -19386352.971% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -300.625% |
| Krystal Biotech, Inc. | 160.42 Million USD | -50.949% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 10.519% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 30.421% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -11128.181% |
| MannKind Corporation | 125.59 Million USD | -92.809% |
| Ikena Oncology, Inc. | 84.57 Million USD | -186.321% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -2410.231% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -170.267% |
| Gossamer Bio, Inc. | 183.75 Million USD | -31.782% |
| CohBar, Inc. | 12.38 Million USD | -1854.764% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -377.411% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -777.971% |
| Legend Biotech Corporation | 583.14 Million USD | 58.473% |
| Mural Oncology plc | 192.07 Million USD | -26.079% |
| Disc Medicine, Inc. | 91.12 Million USD | -165.747% |
| Champions Oncology, Inc. | 28.11 Million USD | -761.48% |
| REGENXBIO Inc. | 321.15 Million USD | 24.597% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -4416.908% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -334.325% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -521.555% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -111.76% |
| Vaxart, Inc. | 90.72 Million USD | -166.916% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -2742.274% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -465.877% |
| Cellectis S.A. | 97.32 Million USD | -148.831% |
| Longeveron Inc. | 21.25 Million USD | -1039.586% |
| Repare Therapeutics Inc. | 167.35 Million USD | -44.698% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 82.205% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -220.13% |
| Revolution Medicines, Inc. | 498.76 Million USD | 51.448% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -3540.439% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -450.944% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -224.657% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -247.759% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -2089.53% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 94.929% |
| Denali Therapeutics Inc. | 527.23 Million USD | 54.069% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2697.406% |
| Veru Inc. | 101.34 Million USD | -138.941% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -934.571% |
| Cingulate Inc. | 22.75 Million USD | -964.019% |
| Passage Bio, Inc. | 108.38 Million USD | -123.419% |
| Context Therapeutics Inc. | 25.07 Million USD | -865.843% |
| Exicure, Inc. | 14.07 Million USD | -1620.389% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -17.518% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -459.253% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -2538.709% |
| Nuvalent, Inc. | 149.49 Million USD | -61.99% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -2901.921% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -133.634% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -1029.013% |
| OmniAb, Inc. | 83.89 Million USD | -188.649% |
| Anew Medical, Inc. | 1.3 Million USD | -18515.803% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -639.11% |
| Lipocine Inc. | 15.08 Million USD | -1505.834% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -253.454% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -217.998% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -500.685% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -110.864% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -981.853% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 63.538% |
| Ocugen, Inc. | 71.56 Million USD | -238.371% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -157.987% |
| Q32 Bio Inc. | 92.68 Million USD | -161.288% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -1043.676% |
| Alumis Inc. Common Stock | 158.17 Million USD | -53.098% |
| Equillium, Inc. | 50.6 Million USD | -378.524% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -288.043% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -1641.477% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -1183.65% |
| Dominari Holdings Inc. | 23.83 Million USD | -915.993% |
| Edesa Biotech, Inc. | 9.22 Million USD | -2525.7% |
| vTv Therapeutics Inc. | 11.9 Million USD | -1933.778% |
| Bio-Techne Corporation | 563.03 Million USD | 56.99% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 40.764% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 9.895% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -83.072% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -1580.397% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -47.934% |
| Nkarta, Inc. | 131.65 Million USD | -83.944% |
| BioCardia, Inc. | 12.12 Million USD | -1897.871% |
| Iterum Therapeutics plc | 47.46 Million USD | -410.158% |